Swedish Orphan Biovitrum AB (publ)
F:B6E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swedish Orphan Biovitrum AB (publ)
F:B6E
|
SE |
|
A
|
Asia Pacific Investment JSC
VN:API
|
VN |
|
A
|
Abl Group ASA
OSE:ABL
|
NO |
|
K
|
Kone Oyj
XMUN:KC4
|
FI |
|
T
|
Trip.com Group Ltd
F:CLV
|
CN |
|
T
|
Takeda Pharmaceutical Co Ltd
XMUN:TKD
|
JP |
|
SIGNA Sports United NV
F:K2S
|
DE |
|
Money Forward Inc
F:47D
|
JP |
Wall St Price Targets
B6E Price Targets Summary
Swedish Orphan Biovitrum AB (publ)
According to Wall Street analysts, the average 1-year price target for B6E is 31.71 EUR with a low forecast of 21.15 EUR and a high forecast of 37.83 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is B6E's stock price target?
Price Target
31.71
EUR
According to Wall Street analysts, the average 1-year price target for B6E is 31.71 EUR with a low forecast of 21.15 EUR and a high forecast of 37.83 EUR.
What is the Revenue forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 23%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Net Income forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
50%
The compound annual growth rate for Net Income over the next 8 years is 50%.
